A Review Study of the effect of COVID-19 on Diabetic patients
Article Sidebar
Main Article Content
Abstract
Coronavirus disease 2019 (CoVID-19), which has spread widely around the world, has had a major impact on the health of individuals, especially those suffering from chronic diseases. One of these diseases is diabetes, which is considered one of the common diseases, main entry receptor for SARS-CoV-2 virus is Angiotensin-converting enzyme 2 (ACE2). Many patients with diabetes suffered from high blood sugar after their infected with Covid-19, in addition to the effect of insulin and its relationship to mortality. Studies have also indicated that chronic inflammation leads to the development of the disease and insulin resistance. Inflammation activating plasmin has an effect on D-dimer, leading to its increase، this increase also leads to mortality. Patients older than 50 years old were more likely to be affected by CoVID-19.
The aim behind this study is to explore this link to be managed appropriately, as people with diabetes need to control their sugar levels because imbalances in these ratios may lead to an increase in the effects of covid-19 infection.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Rhys Williams, Stephen Colagiuri, Reem Almutairi, 2019. IDF diabetes atlas, 9th edition. International Diabetes Federation.
Boddu, S. K., Aurangabadkar, G., & Kuchay, M. S. (2020). New onset diabetes, type 1 diabetes and COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(6), 2211-2217.Care, D. (2022). Care in diabetes—2022. Diabetes care, 45, S17.
Care, D. (2022). Care in diabetes—2022. Diabetes care, 45, S17.
American Diabetes Association. (2020). 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes care, 43(Supplement_1), S14-S31.
Kleinwechter, H. (2020). Diabetes and pregnancy—update 2020. Der Diabetologe, 16, 470-477.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506.
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., ... & Wang, F. S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine, 8(4), 420-422.
World Health Organization, 2008. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., ... & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet, 395(10223), 507-513.
Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281-292.
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, 46, 586-590.
Al-Kuraishy, H. M., Al-Gareeb, A. I., Alblihed, M., Guerreiro, S. G., Cruz-Martins, N., & Batiha, G. E. S. (2021). COVID-19 in relation to hyperglycemia and diabetes mellitus. Frontiers in cardiovascular medicine, 8, 644095.
Nassar, M., Nso, N., Gonzalez, C., Lakhdar, S., Alshamam, M., Elshafey, M., ... & Rizzo, V. (2021). COVID-19 vaccine-induced myocarditis: case report with literature review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(5), 102205.
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H., Müller, M. A., Dijkman, R., ... & Haagmans, B. L. (2013). Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 495(7440), 251-254.
Bornstein, S. R., Rubino, F., Khunti, K., Mingrone, G., Hopkins, D., Birkenfeld, A. L., ... & Ludwig, B. (2020). Practical recommendations for the management of diabetes in patients with COVID-19. The lancet Diabetes & endocrinology, 8(6), 546-550.
En México, R. H. D. N. (1998). Dirección General de Epidemiología. Secretaría de Salud.
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., ... & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama, 323(11), 1061-1069.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ... & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), 1054-1062.
Feldman, E. L., Savelieff, M. G., Hayek, S. S., Pennathur, S., Kretzler, M., & Pop-Busui, R. (2020). COVID-19 and diabetes: a collision and collusion of two diseases. Diabetes, 69(12), 2549-2565.
Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. (2020). Type 2 diabetes and its impact on the immune system. Current diabetes reviews, 16(5), 442-449.
Li, H., Tian, S., Chen, T., Cui, Z., Shi, N., Zhong, X., ... & Zheng, J. (2020). Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19. Diabetes, obesity and metabolism, 22(10), 1897-1906.
Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. Nature reviews immunology, 20(5), 269-270.
Bloomgarden, Z. T. (2020). Diabetes and COVID‐19. Journal of diabetes, 12(4), 347-348.
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., ... & Horwitz, L. I. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. bmj, 369.
Ioannou, G. N., Locke, E., Green, P., Berry, K., O’Hare, A. M., Shah, J. A., ... & Fan, V. S. (2020). Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection. JAMA network open, 3(9), e2022310-e2022310.
Kumar Nathella, P., & Babu, S. (2017). Influence of diabetes mellitus on immunity to human tuberculosis. Immunology, 152(1), 13-24.
Barron, E., Bakhai, C., Kar, P., Weaver, A., Bradley, D., Ismail, H., ... & Valabhji, J. (2020). Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet Diabetes & endocrinology, 8(10), 813-822.
Tartof, S. Y., Qian, L., Hong, V., Wei, R., Nadjafi, R. F., Fischer, H., ... & Murali, S. B. (2020). Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Annals of internal medicine, 173(10), 773-781.
Kleinwechter, H. (2020). Diabetes and pregnancy—update 2020. Der Diabetologe, 16, 470-477.
Desvars-Larrive, A., Dervic, E., Haug, N., Niederkrotenthaler, T., Chen, J., Di Natale, A., ... & Thurner, S. (2020). A structured open dataset of government interventions in response to COVID-19. Scientific data, 7(1), 285.
Akbar, D. H. (2001). Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta diabetologica, 38, 77-82.
Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020). COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The lancet Diabetes & endocrinology, 8(9), 782-792.
Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The lancet respiratory medicine, 8(4), e21.
Eketunde, A. O., Mellacheruvu, S. P., & Oreoluwa, P. (2020). A review of postmortem findings in patients with COVID-19. Cureus, 12(7).
Codo, A. C., Davanzo, G. G., de Brito Monteiro, L., de Souza, G. F., Muraro, S. P., Virgilio-da-Silva, J. V., ... & Moraes-Vieira, P. M. (2020). Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell metabolism, 32(3), 437-446.
Holman, N., Knighton, P., Kar, P., O'Keefe, J., Curley, M., Weaver, A., ... & Valabhji, J. (2020). Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The lancet Diabetes & endocrinology, 8(10), 823-833.
Zhu, L., She, Z. G., Cheng, X., Qin, J. J., Zhang, X. J., Cai, J., ... & Li, H. (2020). Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell metabolism, 31(6), 1068-1077.
Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., ... & Hu, D. (2020). Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes/metabolism research and reviews, 36(7), e3319.
Tian, S., Xiong, Y., Liu, H., Niu, L., Guo, J., Liao, M., & Xiao, S. Y. (2020). Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern Pathology, 33(6), 1007-1014.
Woolcott, O. O., & Castilla-Bancayán, J. P. (2021). The effect of age on the association between diabetes and mortality in adult patients with COVID-19 in Mexico. Scientific Reports, 11(1), 8386.
Ciardullo, S., Zerbini, F., Perra, S., Muraca, E., Cannistraci, R., Lauriola, M., ... & Perseghin, G. (2021). Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. Journal of endocrinological investigation, 44, 843-850.
Zheng, F., Tang, W., Li, H., Huang, Y. X., Xie, Y. L., & Zhou, Z. G. (2020). Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. European Review for Medical & Pharmacological Sciences, 24(6).
Sardu, C., D’Onofrio, N., Balestrieri, M. L., Barbieri, M., Rizzo, M. R., Messina, V., ... & Marfella, R. (2020). Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control?. Diabetes care, 43(7), 1408-1415.
Muniyappa, R., & Gubbi, S. (2020). COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism.
Delamaire, M., Maugendre, D., Moreno, M., Le Goff, M. C., Allannic, H., & Genetet, B. (1997). Impaired leucocyte functions in diabetic patients. Diabetic Medicine, 14(1), 29-34.
Papachristou, S., Stamatiou, I., Stoian, A. P., & Papanas, N. (2021). New-onset diabetes in COVID-19: time to frame its fearful symmetry. Diabetes Therapy, 12, 461-464.
Knapp, S. (2013). Diabetes and infection: Is there a link?-A mini-review. Gerontology, 59(2), 99-104.
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian Journal of Cardiology, 34(5), 575-584.
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., ... & Terrier, B. (2020). Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 369(6504), 718-724.
Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(4), 303-310.
Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18(4), 844-847.